DJIA 17,444.97 57.76 0.33%
NASDAQ 4,703.67 22.17 0.47%
S&P 500 2,035.15 5.60 0.28%
market minute promo

GlaxoSmithKline (NYSE: GSK)

45.49 0.33 (0.73%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

GSK $45.48 0.71%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $45.45
Previous Close $45.16
Daily Range $45.23 - $45.57
52-Week Range $41.25 - $56.73
Market Cap $109.3B
P/E Ratio 15.52
Dividend (Yield) $2.45 (5.9%)
Ex-Dividend Date
Dividend Pay Date
11/05/14
01/08/15
Volume 1,948,087
Average Daily Volume 4,172,961
Current FY EPS $2.98

Sector

Healthcare

Industry

Drugs

GlaxoSmithKline (GSK) Description

The Company is a global healthcare group which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter medicines and health-related consumer products. Website: http://www.gsk.com/

News & Commentary

A Sad Reality: 3 of Healthcare's Top 5 Dividends Probably Aren't Sustainable

Three of healthcare's top five high-yield dividend stocks are probably going to cut their payouts sooner than later.

What Investors Should Do About Imminent Obesity Drug Approvals In Europe

Pfizer's Prevenar 13 Wins CHMP Backing for Expanded Use - Analyst Blog

GlaxoSmithKline Expands Its Portfolio Of Medicines In The US For Patients With Asthma And COPD

This Popular Beverage Could Be Responsible For a 20% Reduction in Melanoma Risk

The good news: this beverage reduced the risk of an aggressive form of skin cancer by 20% in a very large study. The better news: 83% of you are already consuming this beverage on a daily basis!

Benzinga's Weekend M&A Chatter

These 3 Pharmaceutical Companies Control Roughly Half of All Cancer Drug Sales

Global cancer drug sales totaled $91 billion in 2013 and are expected to breach $100 billion in sales sooner than you think. Yet, three big pharmaceutical companies currently control about half of all cancer drug sales.

Here's Why This Year's Flu Vaccine Isn't Working

Have you ever wondered why the effectiveness of the flu vaccine is so erratic from one year to the next? Here's the answer.

Will Novartis' (NVS) Earnings Disappoint Expectations in Q4? - Analyst Blog

3 Health Care Stocks Driving The Sector Higher

See More GSK News...

GSK's Top Competitors

GSK $45.49 (0.73%)
Current stock: GSK
JNJ $102.78 (0.68%)
Current stock: JNJ
NVS $98.52 (-0.41%)
Current stock: NVS
PFE $32.31 (-0.90%)
Current stock: PFE